• Something wrong with this record ?

Assessing regulated cell death modalities as an efficient tool for in vitro nanotoxicity screening: a review

A. Tkachenko, A. Onishchenko, V. Myasoedov, S. Yefimova, O. Havranek

. 2023 ; 17 (3) : 218-248. [pub] 20230421

Language English Country England, Great Britain

Document type Review, Journal Article, Research Support, Non-U.S. Gov't

Nanomedicine is a fast-growing field of nanotechnology. One of the major obstacles for a wider use of nanomaterials for medical application is the lack of standardized toxicity screening protocols for assessing the safety of newly synthesized nanomaterials. In this review, we focus on less frequently studied nanomaterials-induced regulated cell death (RCD) modalities, including eryptosis, necroptosis, pyroptosis, and ferroptosis, as a tool for in vitro nanomaterials safety evaluation. We summarize the latest insights into the mechanisms that mediate these RCDs in response to nanomaterials exposure. Comprehensive data from reviewed studies suggest that ROS (reactive oxygen species) overproduction and ROS-mediated pathways play a central role in nanomaterials-induced RCDs activation. On the other hand, studies also suggest that individual properties of nanomaterials, including size, shape, or surface charge, could determine specific toxicity pathways with consequent RCD induction as well. We anticipate that the evaluation of RCDs can become one of the mechanism-based screening methods in nanotoxicology. In addition to the toxicity assessment, evaluation of necroptosis-, pyroptosis-, and ferroptosis-promoting capacity of nanomaterials could simultaneously provide useful information for specific medical applications as could be their anti-tumor potential. Moreover, a detailed understanding of molecular mechanisms driving nanomaterials-mediated induction of immunogenic RCDs will substantially aid novel anti-tumor nanodrugs development.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010510
003      
CZ-PrNML
005      
20250120131044.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/17435390.2023.2203239 $2 doi
035    __
$a (PubMed)37083543
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Tkachenko, Anton $u BIOCEV, First Faculty of Medicine, Charles University, Vestec, Czechia $u Research Institute of Experimental and Clinical Medicine, Kharkiv National Medical University, Kharkiv, Ukraine $1 https://orcid.org/0000000210291636 $7 xx0328071
245    10
$a Assessing regulated cell death modalities as an efficient tool for in vitro nanotoxicity screening: a review / $c A. Tkachenko, A. Onishchenko, V. Myasoedov, S. Yefimova, O. Havranek
520    9_
$a Nanomedicine is a fast-growing field of nanotechnology. One of the major obstacles for a wider use of nanomaterials for medical application is the lack of standardized toxicity screening protocols for assessing the safety of newly synthesized nanomaterials. In this review, we focus on less frequently studied nanomaterials-induced regulated cell death (RCD) modalities, including eryptosis, necroptosis, pyroptosis, and ferroptosis, as a tool for in vitro nanomaterials safety evaluation. We summarize the latest insights into the mechanisms that mediate these RCDs in response to nanomaterials exposure. Comprehensive data from reviewed studies suggest that ROS (reactive oxygen species) overproduction and ROS-mediated pathways play a central role in nanomaterials-induced RCDs activation. On the other hand, studies also suggest that individual properties of nanomaterials, including size, shape, or surface charge, could determine specific toxicity pathways with consequent RCD induction as well. We anticipate that the evaluation of RCDs can become one of the mechanism-based screening methods in nanotoxicology. In addition to the toxicity assessment, evaluation of necroptosis-, pyroptosis-, and ferroptosis-promoting capacity of nanomaterials could simultaneously provide useful information for specific medical applications as could be their anti-tumor potential. Moreover, a detailed understanding of molecular mechanisms driving nanomaterials-mediated induction of immunogenic RCDs will substantially aid novel anti-tumor nanodrugs development.
650    _2
$a lidé $7 D006801
650    _2
$a reaktivní formy kyslíku $x metabolismus $7 D017382
650    12
$a nanostruktury $x toxicita $7 D049329
650    _2
$a nanotechnologie $7 D036103
650    _2
$a nanomedicína $7 D050997
650    _2
$a nekroptóza $7 D000079302
650    12
$a nádory $7 D009369
655    _2
$a přehledy $7 D016454
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Onishchenko, Anatolii $u Research Institute of Experimental and Clinical Medicine, Kharkiv National Medical University, Kharkiv, Ukraine $1 https://orcid.org/0000000221222361
700    1_
$a Myasoedov, Valeriy $u Department of Medical Biology, Kharkiv National Medical University, Kharkiv, Ukraine
700    1_
$a Yefimova, Svetlana $u Institute for Scintillation Materials, National Academy of Sciences of Ukraine, Kharkiv, Ukraine $1 https://orcid.org/0000000320921950
700    1_
$a Havranek, Ondrej $u BIOCEV, First Faculty of Medicine, Charles University, Vestec, Czechia $u Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czechia $1 https://orcid.org/0000000158263557 $7 xx0128548
773    0_
$w MED00192827 $t Nanotoxicology $x 1743-5404 $g Roč. 17, č. 3 (2023), s. 218-248
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37083543 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20250120131042 $b ABA008
999    __
$a ok $b bmc $g 1963125 $s 1196775
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 17 $c 3 $d 218-248 $e 20230421 $i 1743-5404 $m Nanotoxicology $n Nanotoxicology $x MED00192827
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...